Development of Immunotoxicity Testing Strategies for Immunomodulatory Drugs
|
|
- Jewel Campbell
- 6 years ago
- Views:
Transcription
1 Toxicologic Pathology, 40: , 2012 Copyright # 2012 by The Author(s) ISSN: print / online DOI: / Development of Immunotoxicity Testing Strategies for Immunomodulatory Drugs THOMAS T. KAWABATA AND ELLEN W. EVANS Drug Safety R&D, Pfizer, Inc., Groton, Connecticut, USA ABSTRACT The ICH S8 immunotoxicity testing guideline for human pharmaceuticals was published in 2006 and was intended to provide guidance for assessing the immunotoxicity potential of low-molecular-weight drugs that are not intended to alter the immune system. For drugs intended to modulate the immune system, immunotoxicity testing strategies are generally developed on a case-by-case approach since the targets, intended patient population, and mechanisms of action of the test compound will determine the type of testing needed. Some of the general principles of ICH S8, however, may be applied to immunotoxicity testing strategies for immunomodulatory drugs. A weight-of-evidence approach using factors discussed in ICH S8 in concert with an assessment of the potential value of additional immunotoxicity testing should be considered. For most situations, immunotoxicity studies with immunomodulatory compounds evaluate off-target effects on the immune system and exaggerated pharmacology. The potential use of data from these studies and considerations such as translatability to humans are discussed. Keywords: immunotoxicity; immunotoxicology; immunomodulation; immunosuppression. INTRODUCTION The development of immunotoxicity testing strategies for drugs intended to modify the immune response can be a very challenging and controversial area. For the majority of situations, immunotoxicity strategies are best approached on a case-by-case basis rather than in a prescriptive fashion. Thus, in practice, the strategies may vary significantly between pharmaceutical companies, and regulatory agencies. The primary gray area of immunotoxicity testing strategies is in deciding if additional immunotoxicity testing is needed (assays beyond that normally done for standard toxicity studies [STS]). With some situations, only limited immunotoxicity testing may be needed since the effects on the immune system may be well characterized in nonclinical pharmacodynamic, efficacy, and general toxicity studies or because changes in immune response would be expected and predictable based on the nature of the intended target. On the other hand, there may be targets for which the biology is not fully understood and the types of pharmacodynamics and efficacy studies conducted do Address correspondence to: Thomas T. Kawabata, Drug Safety R&D, Pfizer, Inc., MS , Groton, CT 06340; Conflict of interest/financial disclosure: The authors claim no conflict of interest and are employees of Pfizer, Inc. Abbreviations: BrdU, bromodeoxyuridine; EBV, Epstein Barr virus; FDA, Food and Drug Administration; HuLA, human lymphocyte activation; HSC, hematopoietic stem cells; ICH, International Conference on Harmonization; IMTX, immunotoxicity; JPMA, Japan Pharmaceutical Manufacturers Association; MHLW, Ministry of Health and Labor Welfare; NOD, nonobese diabetic; PBMC, peripheral blood mononuclear cells; PhARMA, Pharmaceutical Manufacturers of America; RAG, recombinant activating gene; RA, rheumatoid arthritis; TDAR, T-dependent antibody response; WoE, weight of evidence. not assess multiple arms of the immune response beyond those targeted for efficacy. The goal of this article is to discuss the history and current immunotoxicity testing guidelines and how they may be applied to developing an immunotoxicity testing strategy for immunomodulatory drugs. It will describe a general thought process and considerations for deciding if additional immunotoxicity studies should be done, how the additional immunotoxicity data will be used, and whether such studies will provide value to decisions made during the drug development process. The focus will be on immunomodulatory drugs that may suppress the immune response and possibly increase the risk for infections and malignancies. Finally, new approaches to address translatability of immunotoxicity from toxicity testing species to humans will be discussed. HISTORY OF IMMUNOTOXICITY TESTING GUIDELINES To better understand the current immunotoxicity testing guidelines for pharmaceuticals, a brief history of previous guidance documents is provided. The Committee for Proprietary Medicinal Products (2000) of the European Agency for the Evaluation of Medicinal Products (EMEA; currently referred to as EMA) updated the Note for Guidance on Repeat Dose Toxicity testing in 2000, including a section on immunotoxicity testing (section 6.4). This section recommends that all new medicinal products be screened for immunotoxic potential in at least one repeat-dose toxicity study. Initial screening for immunotoxicity consisted of standard toxicity testing, which includes hematology, lymphoid organ weights, histopathology of lymphoid tissues, and bone marrow cellularity. In addition to standard toxicity data, distribution of lymphocyte subsets (immunophenotyping) and natural killer cell activity were required as part of initial screening. According to the guidance 288
2 Vol. 40, No. 2, 2012 KAWABATA AND EVANS 289 document, if the latter two assays are not available, the primary T-dependent antibody response (TDAR) should be evaluated. These types of assays were primarily focused on detecting immunosuppression. In 2002, the Center for Drug Evaluation and Research of the U.S. Food and Drug Administration (FDA) published a guidance document titled Immunotoxicology Evaluation of Investigational New Drugs. This guidance focused on recommendations for testing approaches to characterize the effects of drugs on the immune system and when these studies should be conducted. In contrast to the EMA guidance, the FDA guideline included information on immunosuppression as well as other areas of immunotoxicology: immunogenicity, hypersensitivity, autoimmunity, and adverse immunostimulation. For immunosuppression, it was recommended that standard repeat-dose toxicity studies be used as the first tier of testing. If evidence of immunosuppression is found, follow-up studies may be appropriate. The two assays in particular that were recommended were the TDAR and immune cell phenotyping by flow cytometry or immunohistochemistry. With the publication of the EMA guidance document, the Ministry of Health and Labor Welfare (MHLW) of Japan and the Japan Pharmaceutical Manufacturers Association (JPMA) initiated the preparation of their own guidance document and discussions at meetings of the International Conference on Harmonization (ICH) in 2001 to develop a harmonized immunotoxicity testing guideline. Soon after the publication of the FDA immunotoxicity guidance document in 2002, the ICH endorsed the proposal from the MHLW and JPMA to prepare a harmonized guideline. An expert working group of representatives from the MHLW, JPMA, EMA, European Federation of Pharmaceutical Industries and Associations, FDA, and Pharmaceutical Research and Manufactures of America was formed to prepare the guidance. ICH S8 IMMUNOTOXICITY TESTING GUIDANCE After several years of discussions, the ICH S8 guidance on Immunotoxicity Studies for Human Pharmaceuticals was finalized and came into operation in May 2006 (ICH 2005). The scope of the S8 was focused on nonclinical testing for unintended immunosuppression and immunoenhancement. It excluded recommendations for biotechnology-derived pharmaceutical products (biologicals) since these were covered by ICH S6. Recommendations for hypersensitivity and autoimmunity testing were not included, and existing guidelines for these areas remained in force (primarily the 2002 FDA guidance). The key decision point for the guidance was the weightof-evidence (WoE) review of the factors to consider in the evaluation of potential immunotoxicity (Figure 1). These factors include results from standard toxicity studies, pharmacological properties of the test compound, the intended patient population, structural similarity of known immunosuppressive compounds, accumulation of the test compound in cells or organs of the immune system, and signs from clinical trials. If the WoE review indicates that additional immunotoxicity FIGURE 1. ICH S8 Decision Tree for Immunotoxicity (imtx) Testing. testing is warranted, then additional immunotoxicity tests should be conducted. The types of additional immunotoxicity tests selected should be based on the findings from the list of factors to consider (Fig. 1). If significant immunomodulation is observed with these additional tests, the sponsors need to determine if there is sufficient data for risk assessment and management of the potential immunotoxic effects. If not, additional studies may be needed. CURRENT THINKING ON IMMUNOTOXICITY TESTING OF IMMUNOMODULATORY DRUGS Since the scope of ICH S8 does not specifically include drugs intended to modify the immune response, the current practice for determining immunotoxicity testing strategies for immunomodulatory drugs is on a case-by-case basis. This practice makes the most sense since the type of testing should be based on the mechanism of action of the immunomodulatory drugs, the indication and use (acute vs. chronic), and intended patient population. It is not feasible or practical to develop guidelines that would apply to all situations because it would likely result in unnecessary testing. There is general agreement that the case-by-case approach is the most appropriate since it provides the flexibility needed to do the best science appropriate for the specific drug being developed. With the increasing number and diversity of immunomodulatory drugs in development along with inconsistencies in immunotoxicity testing practice between companies and requests for immunotoxicity testing by regulatory agencies, a workshop was held to discuss this topic in May 2007 (summarized in Piccotti et al. 2009). The primary goal of the meeting was to discuss testing strategies and identify key gaps in nonclinical and clinical immunotoxicity testing for anti-inflammatory and immunomodulatory drugs. Stakeholders from regulatory agencies,
3 290 IMMUNOTOXICITY TESTING STRATEGIES TOXICOLOGIC PATHOLOGY Immunomodulatory drug is being developed Conduct imtx assays in tox studies Concerns about translation Imtx data not used Consider including immuno-end points in clinical studies How can we make this assessment with non-clinical studies? Challenges regarding assay availability, costs and logistics Concerns about interpretation of data in regards to clinical impact (e.g. infections, malignancies) Primary reliance on infection and malignancy rate data Need assessment of potential infection and malignancy risk earlier in the development process FIGURE 2. Worst-Case Scenario of a Hypothetical Conundrum on Immunotoxicity Testing of Immunomodulatory Drugs academia, and industry were present and included nonclinical scientists and clinicians. There was consensus among participants that immunotoxicity testing for immunomodulatory drugs should continue to be conducted on a case-by-case basis where a WoE review of the different causes for concern drive the immunotoxicity testing strategy. Immunotoxicity testing may be conducted to evaluate off-target immunological effects and/or exaggerated pharmacology. The major gaps identified at this workshop were as follows: 1. Lack of appropriate testing methods for both nonclinical and clinical immunotoxicity testing. 2. Translation of immunotoxicity findings in animals to humans. 3. Determining when additional immunotoxicity testing would be helpful (triggers for testing). 4. Interpretation of changes in clinical immunological assays to actual risk for infections or malignancies. CHALLENGES IN DEVELOPING IMMUNOTOXICITY TESTING STRATEGIES The key nonclinical and clinical immunotoxicity testing gaps noted above have resulted in a conundrum that may play out as companies decide on the appropriate testing strategies for immunomodulatory drugs. The diagram shown in Figure 2 illustrates the worst-case scenario of this conundrum. The decisions described may not be applicable for all immunomodulatory drugs but for some components may play an important role in the decision process. The decisions regarding the immunotoxicity testing strategy will depend on a variety of factors including but not limited to the drug target and the availability of validated assays. As shown in Figure 2, it is possible to include immunotoxicity endpoints in repeat-dose toxicology studies (beyond endpoints included in STS) or to conduct stand-alone immunotoxicity studies (e.g., rat TDAR). However, there may be concerns about the translation of any findings to humans, so the data may have only minimal impact FIGURE 3. Thought Process in Developing an Immunotoxicity Testing Strategy on future development decisions. There also may be situations in which nonclinical immunotoxicity studies are not conducted since adverse immunomodulation may best be monitored in clinical trials. In addition, there may be significant challenges with incorporating the assays (e.g., technical challenges, lack of assay availability or expertise at testing sites, costs) in clinical studies. Concerns about interpreting the clinical laboratory data may also arise. For example, how much of a decrease in T-cell function will be associated with an increased incidence of infections and malignancies? This may then lead to the reliance of infection data and malignancy data observed in long-term clinical trials, but this occurs very late in the drug development process, so testing earlier in the development process may need to be reevaluated. This takes us back to the start of the conundrum. Therefore, to navigate around this issue, a better understanding is needed of the triggers or rationale for including nonclinical immunotoxicity studies in the thought process for toxicity testing of immunomodulatory compounds. In addition, methods to enhance our confidence in translating nonclinical data to humans are needed. PROPOSED THOUGHT PROCESS IN DEVELOPING AN IMMUNOTOXICITY TESTING STRATEGY It may be possible to apply the principles of the ICH S8 guidance document to immunomodulatory compounds by including additional considerations in the WoE review in deciding if additional immunotoxicity testing may be of value. For this thought process, one first needs to think about the key issue with immunomodulatory drugs that are immunosuppressive, that being the increased risk for infection and malignancies (Fig. 3). Second, one needs to evaluate how and if additional immunotoxicity data will help address the key issue. In addition, nonclinical pharmacodynamic and efficacy studies conducted during the discovery process need to be considered;
4 Vol. 40, No. 2, 2012 KAWABATA AND EVANS 291 TABLE 1. Potential Uses of Immunotoxicity Data Determined by Levels of Confidence in Translatability Level 1 confidence (hazard ID) Determine potential off-target effects Characterize the exaggerated pharmacological effects Identify potential unsuspected bad actors Identify potential biomarkers that can be used in future studies Level 2 confidence (risk assessment) All of the above Determine a safety margin or therapeutic index Competitor comparison Commercial viability Ranking compounds data from these studies may be adequate to characterize hazard or risk or may suggest a need for additional testing. In general, immunotoxicity studies for immunomodulatory drugs are primarily used to understand the potential immunological off-target and exaggerated pharmacologic effects. The findings from these studies may help to: (1) identify compounds that may unexpectedly have a significant or unacceptable impact on the immune response (so-called bad actors ), (2) rank compounds, (3) determine reversibility of these effects on the immune system, (4) determine a safety margin or therapeutic index for an effect on the immune system, (5) assist in the determination of commercial viability, and (6) identify potential biomarkers of immunomodulation (pharmacodynamics or immunotoxicity) for future nonclinical and clinical studies. The potential value of this type of information will depend on a number of factors for a particular compound such as therapeutic indication, patient population, length of drug therapy, and standard-of-care therapy. The value and utility of the data generated will also depend on the level of confidence regarding the translatability of the data to humans. This can best be understood by dividing levels of confidence and translatability into three levels. The first level simply involves translating the potential hazard from the animal to human (hazard identification). The second level involves translating alterations in immune function in animals to those in humans at equivalent exposure levels (risk assessment). The third and most difficult to determine is whether a specific alteration in an immunotoxicity endpoint correlates with an increased risk for infections or malignancies in humans. The potential uses of the data with the first and second level of confidence are shown in Table 1. Additional value from immunotoxicity testing data may be obtained with the second level of confidence as the risk assessment process can be applied, and thus a safety margin or therapeutic index may be determined. The level of confidence in data translation will depend on differences between the test species and humans that may be target (e.g., cytokine receptor) or compound specific (e.g., monoclonal antibody, low-molecular-weight chemical). This may include the distribution of the drug target among different tissues and cell types, sequence homology of the target, and the role of different cell types in generating immune responses (e.g., TDAR). However, in most situations, the confidence of translation between species and with humans is unknown and difficult to ascertain. Thus, as with toxicities in other organ systems, it is assumed that the toxicity observed in the toxicology species may identify target organs in humans and be used to determine a no adverse effect level unless data to the contrary are available. APPLICATION OF PROPOSED THOUGHT PROCESS TO A HYPOTHETICAL CASE STUDY To better understand the thought process described in the previous section, a hypothetical case study is discussed below. A monoclonal antibody (Mab) against receptor X on macrophages has been shown to inhibit the inflammatory responses in various mouse models through the inhibition of proinflammatory cytokine production. Although receptor X is primarily expressed on macrophages, low levels of receptor X have been reported on T and dendritic cells. The expression levels in the different cell types may differ between rats, monkeys, and humans. The project team plans to develop a Mab for receptor X (anti-x) for the treatment of rheumatoid arthritis (RA) and requests that an immunotoxicity testing strategy be developed. Evaluating potential off-target immunological effects and exaggerated pharmacology may be helpful in the early stages of development to determine if targeting receptor X will have a significant impact on multiple arms of immune responses (identifying bad actors ) and assist in the determination if anti-x will be commercially viable. For example, if anti-x dramatically inhibits adaptive immune responses with a low safety margin or therapeutic index, it may not be commercially competitive in comparison to the standard of care since most of the currently used RA therapies have a slight to moderate impact on adaptive immune responses. To assess the potential impact on adaptive immune responses, a holistic in vivo assay that assesses adaptive immune responses may be helpful. The in vivo TDAR is one of the most commonly used holistic approaches. This assay has been widely validated/qualified for sensitivity by using marketed immunosuppressive drugs with different mechanisms (e.g., cyclosporine A, dexamethasone, cyclophosphamide) and is commonly used in mouse, rat, and monkey immunotoxicity studies and occasionally in dogs. The level of confidence for translatability of the TDAR may vary with different targets or mechanisms of action, particularly if the target or biology in the nonclinical species varies from that of humans. This needs to be considered in determining if the TDAR should be conducted. Ex vivo or in vitro assays that specifically assess T-cell or dendritic cell function may also be helpful, particularly to determine the mechanism if there is an unexpected effect on the TDAR. These assays may also provide information that could help in determining the therapeutic index or safety margin when compared with efficacious exposure levels in mouse models of inflammation. Since inhibition of receptor X function at or near 100% may also theoretically inhibit macrophage host defense mechanisms, in vivo or in vitro exaggerated
5 292 IMMUNOTOXICITY TESTING STRATEGIES TOXICOLOGIC PATHOLOGY pharmacology studies that evaluate macrophage phagocytosis and killing of bacteria may be included. For example, if concentrations that inhibit receptor X mediated cytokine production are significantly lower than concentrations that inhibit macrophage killing of bacteria, there may be increased confidence of a lower risk for infections at efficacious doses (at least for infections in which macrophage killing plays an important role in host defense). In addition, these findings may refine or enhance the clinical monitoring strategy. For example, if there is decreased macrophage killing of fungi at clinically relevant concentrations in comparison to other pathogens, clinical studies in areas with high risk for histoplasmosis (e.g., Ohio River Valley) or other fungal infections with regional distributions may be monitored more intensely. APPROACHES TO ENHANCE CONFIDENCE IN TRANSLATABILITY To enhance the confidence of translatability of nonclinical immunotoxicity data, new approaches that use human cells may be helpful. The in vitro human lymphocyte activation (HuLA) assay (Collinge et al. 2010) may be used early in the development process since it requires low amounts of test compound and has a medium throughput. In contrast to other in vitro lymphocyte stimulation assays that use mitogens (e.g., conconavlin A, phytohemagglutin) or stimulating antibodies (e.g., anti-cd3, anti-cd40), this method evaluates influenzaspecific responses and thereby evaluates the effect of a test compound on multiple cells types and processes. The HuLA assay involves preparation of peripheral blood mononuclear cells (PBMCs) from healthy donors that had been recently vaccinated with the influenza vaccine. The PBMCs may be frozen and used when needed. PBMCs are incubated with test compound at different concentrations along with flu antigens (commercially available influenza vaccine). The flu antigens activate flu-specific T and B cells, and the proliferative response is measured by bromodeoxuridine (BrdU) incorporation (immunoassay for BrdU). The 50% inhibitory concentrations (IC50) of several immunosuppressive drugs have been determined in the HuLA assay (cyclosporine A, dexamethasone, mycophenolate, methotrexate). The IC50s were found to be similar to plasma concentrations at therapeutic doses. Additional endpoints may be included in the HuLA assay such as intracellular staining of cytokines by flow cytometry or the generation of flu-specific antibody-forming cells. This assay may be used early in the development process to rank compounds or identify bad actors. In addition, if the TDAR response is decreased in the rat, the HuLA assay may be used to determine if the findings in the rat may be translated to humans. Another approach that may be used in the future are humanized mouse models. These models have significantly improved over the past two decades and currently involve transplanting human hematopoietic stem cells into immunodeficient mouse strains (see history in the review by Brehm, Schultz, and Greiner 2010). One of the more recent models uses non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice with a mutated IL-2 receptor gamma chain (IL2ry null ) which express human HLA Class I heavy and light chains (NSG-HLA-A2-/HHD mice) (Shultz et al. 2010). When CD34þ HSC are transplanted into newborn mice, they develop functional CD4þ and CD8þ T cells in the bone marrow and spleen. Moreover, when infected with Epstein-Barr virus (EBV), they generate functional EBV-specific CD8þ cytotoxic T cells. Another model recently reported used NOD.Rag1KO. IL2RgcKO mice (NOD mice with recombinase-activating gene-1 and IL-2 receptor gamma chain knock out) that express HLA class II molecules (DRAG mice; Danner et al. 2011). Transplantation of adult DRAG mice with human stem cells resulted in a high rate of human T- and B-cell reconstitution. These cells were functional and when immunized with tetanus toxoid, the mice produced a robust tetanus-specific IgG response. Thus, with continual improvement, it may be practical to use these models to evaluate the effects of immunodulatory drugs on the human immune system in the future. CONCLUSIONS Although ICH S8 did not include guidance for drugs intended to suppress or enhance the immune response, some of the principles related to using a WoE approach can be applied. Further considerations in deciding if additional immunotoxicity studies are needed will depend on the value of determining immunological off-target effects and exaggerated pharmacology. The thought process in making this decision is focused on how the data will be used and the level of confidence in the translation of the data from animal studies to humans. In the future, this level of confidence may be enhanced by using in vivo and in vitro methods with human cells of the immune system. REFERENCES Brehm, M. A., Shultz, L. D., and Greiner, D. L. (2010). Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17, Collinge, M., Cole, S. H., Schneider, P. A., Donovan, C. B., Kamperschroer, C., and Kawabata, T. T. (2010). Human lymphocyte activation assay: An in vitro method for predictive immunotoxicity testing. JImmunotoxicol7, Committee for Proprietary Medical Products. (2000). Note for Guidance on Repeated Dose Toxicity. Available at: en_gb/document_library/scientific_guideline/2009/09/wc pdf. Danner, R., Chaudhari, S. N., Rosenberger, J., Surls, J., Richie, T. L., Brumeanu, T. D., and Caseares, S. (2011). Expression of HLA class II molecules in humanized NOD.Rag.1KO.IL2RgckKO mice is critical for development and function of human T and B cells. PLoS ONE 6, e Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services. (2002). Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs. Available at: formation/guidances/ucm pdf. International Conference in Harmonisation. (2005). Harmonised Tripartite Guideline: Immunotoxicity Studies for Human Pharmaceuticals S8. Available at: Piccotti, J. R., Lebrec, H. N., Evans, E., Herzyk, D. J., Hastings, K. L., Burns-Naas,L.A.,Gourley,I.S.,Wierda,D.,andKawabata,T.T.
6 Vol. 40, No. 2, 2012 KAWABATA AND EVANS 293 (2009) Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs. J Immunotoxicol 6, Shultz, L. D., Saito, Y., Najima, Y., Tanaka, S., Ochi, T., Tomizawa, M., Doi, T., Sone, A., Suzuki, N., Fujiwara, H., Yasukawa, M., and Ishikawa, F. (2010). Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/ SCID/IL2rg null humanized mice. Proc Natl Acad Sci U S A 107, For reprints and permissions queries, please visit SAGE s Web site at
IMMUNOTOXICITY STUDIES
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMMUNOTOXICITY STUDIES FOR HUMAN PHARMACEUTICALS
More informationAppropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach
Appropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach Veterinary Pathology 49(2) 357-361 ª The Author(s) 2012 Reprints and permission: sagepub.com/journalspermissions.nav
More informationThe Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System
The Immune System! Functions of the Immune System! Types of Immune Responses! Organization of the Immune System! Innate Defense Mechanisms! Acquired Defense Mechanisms! Applied Immunology A macrophage
More informationUnderstanding immune biomarkers for use in nutrition interventions
NIHR Southampton Biomedical Research Centre in nutrition Understanding immune biomarkers for use in nutrition interventions Philip C. Calder Professor of Nutritional Immunology University of Southampton
More informationICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy
ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Background Regulatory authorities
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationThe ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report Introduction The ICH
More informationEVALUATION DE LA CANCEROGENESE DES MEDICAMENTS QUOI DE NEUF?
1 EVALUATION DE LA CANCEROGENESE DES MEDICAMENTS QUOI DE NEUF? Nigel Roome M.Sc, Ph.D Consultant in Toxicology and Toxicologic Pathology Versailles, France 31.05.2017 nigel.roome@wanadoo.fr 2 Overview
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals. Step 5
European Medicines Agency March 1998 CPMP/ICH/299/95 ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON CARCINOGENICITY: TESTING FOR CARCINOGENICITY
More informationThe Comet Assay Tails of the (Un)expected
The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic
More informationChapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationProf. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology
By Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology Lecture objectives: At the end of the lecture you should be able to: Enumerate features that characterize acquired immune response
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationBlood and Immune system Acquired Immunity
Blood and Immune system Acquired Immunity Immunity Acquired (Adaptive) Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated
More informationThe Lymphatic System and Body Defenses
PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College The Lymphatic System and Body Defenses 12PART B Adaptive Defense System: Third Line of Defense Immune
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationUnit title: The Immune Response System
Unit title: The Immune Response System Unit code: M/601/0228 QCF level: 5 Credit value: 15 Aim This unit develops an understanding of the function and manipulation of the immune system and its abnormalities.
More informationChapter 23 Immunity Exam Study Questions
Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)
More informationImmune Reconstitution Following Hematopoietic Cell Transplant
Immune Reconstitution Following Hematopoietic Cell Transplant Patrick J. Kiel, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Indiana University Simon Cancer Center Conflicts of Interest Speaker Bureau
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationCHAPTER-VII IMMUNOLOGY R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR.
CHAPTER-VII IMMUNOLOGY R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR. The Immune Response Immunity: Free from burden. Ability of an
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationI. Defense Mechanisms Chapter 15
10/24/11 I. Defense Mechanisms Chapter 15 Immune System Lecture PowerPoint Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display. Defense Mechanisms Protect against
More informationPhysiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response
Physiology Unit 3 ADAPTIVE IMMUNITY The Specific Immune Response In Physiology Today The Adaptive Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationRadical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa
Radical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa Figure 1: Major blood cells that differentiate from hematopoietic stem cells. Hematopoietic stem cells differentiate into
More informationDISCOVERING ATCC IMMUNOLOGICAL CELLS - MODEL SYSTEMS TO STUDY THE IMMUNE AND CARDIOVASCULAR SYSTEMS
DISCOVERING ATCC IMMUNOLOGICAL CELLS - MODEL SYSTEMS TO STUDY THE IMMUNE AND CARDIOVASCULAR SYSTEMS James Clinton, Ph.D. Scientist, ATCC February 19, 2015 About ATCC Founded in 1925, ATCC is a non-profit
More informationThe Immune System is the Third Line of Defense Against Infection. Components of Human Immune System
Chapter 17: Specific Host Defenses: The Immune Response The Immune Response Immunity: Free from burden. Ability of an organism to recognize and defend itself against specific pathogens or antigens. Immune
More informationAnimal Models to Understand Immunity
Animal Models to Understand Immunity Hussein El Saghire hesaghir@sckcen.be Innate Adaptive immunity Immunity MAPK and NF-kB TLR pathways receptors Fast Slow Non-specific Specific NOD-like receptors T-cell
More informationTolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationE11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Pediatric Population Step4
E11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Step4 October 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More information4/28/2016. Host Defenses. Unit 8 Microorganisms & The Immune System. Types of Innate Defenses. Defensive Cells Leukocytes
Host Defenses Unit 8 Microorganisms & The Immune System CH 16-18 Host defenses that produce resistance can be either innate or adaptive: Innate: those that protect against any type of invading agent Adaptive:
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationOverview: The immune responses of animals can be divided into innate immunity and acquired immunity.
GUIDED READING - Ch. 43 - THE IMMUNE SYSTEM NAME: Please print out these pages and HANDWRITE the answers directly on the printouts. Typed work or answers on separate sheets of paper will not be accepted.
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationImmune system. Aims. Immune system. Lymphatic organs. Inflammation. Natural immune system. Adaptive immune system
Aims Immune system Lymphatic organs Inflammation Natural immune system Adaptive immune system Major histocompatibility complex (MHC) Disorders of the immune system 1 2 Immune system Lymphoid organs Immune
More informationMicrobiology 204: Cellular and Molecular Immunology
Microbiology 204: Cellular and Molecular Immunology Class meets MWF 1:00-2:30PM (*exceptions: no class Fri Sept 23, Fri Oct 14, Nov 11, or Wed Nov 23) Lectures are open to auditors and will be live-streamed
More informationIntroduction to Immune System
Introduction to Immune System Learning outcome You will be able to understand, at a fundamental level, the STRUCTURES and FUNCTIONS of cell surface and soluble molecules involved in recognition of foreign
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationMONTGOMERY COUNTY COMMUNITY COLLEGE Department of Science LECTURE OUTLINE CHAPTERS 16, 17, 18 AND 19
MONTGOMERY COUNTY COMMUNITY COLLEGE Department of Science LECTURE OUTLINE CHAPTERS 16, 17, 18 AND 19 CHAPTER 16: NONSPECIFIC DEFENSES OF THE HOST I. THE FIRST LINE OF DEFENSE A. Mechanical Barriers (Physical
More informationMon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York.
Course Title: Course Number: Immunology Biol-341/541 Semester: Fall 2013 Location: HS 268 Time: Instructor: 8:00-9:30 AM Tue/Thur Dr. Colleen M. McDermott Office: Nursing Ed 101 (424-1217) E-mail*: mcdermot@uwosh.edu
More informationStandardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities
Standardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities 2 nd WHO Integrated Meeting on development and clinical trials of Influenza vaccines that induce broadly
More informationThe Lymphatic System and Immunity. Chapters 20 & 21
The Lymphatic System and Immunity Chapters 20 & 21 Objectives 1. SC.912.L.14.52 - Explain the basic functions of the human immune system, including specific and nonspecific immune response, vaccines, and
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationDevelopmental Toxicity Study Designs for Preventive Vaccines: Issues and Challenges
Developmental Toxicity Study Designs for Preventive Vaccines: Issues and Challenges Marion F. Gruber, Ph.D. Office of Vaccines Research and Review CBER/FDA HESI Annual Meeting June 8, 2011 Alexandria,
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationChapter 24 The Immune System
Chapter 24 The Immune System PowerPoint Lectures for Biology: Concepts & Connections, Sixth Edition Campbell, Reece, Taylor, Simon, and Dickey Lecture by Edward J. Zalisko Introduction: The Kissing Disease?!?
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationSection 6.1 Defence mechanisms
Section 6.1 Defence mechanisms Defence mechanisms Non-specific mechanisms that do not distinguish between one type of pathogen and another, but respond to all of them in the same way. These mechanisms
More informationall of the above the ability to impart long term memory adaptive immunity all of the above bone marrow none of the above
1. (3 points) Immediately after a pathogen enters the body, it faces the cells and soluble proteins of the innate immune system. Which of the following are characteristics of innate immunity? a. inflammation
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationBasis and Clinical Applications of Interferon
Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance
More informationLESSON 2: THE ADAPTIVE IMMUNITY
Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationGLOBAL BIOANALYSIS CONSORTIUM
GLOBAL BIOANALYSIS CONSORTIUM Scope and Regulations Harmonization Team: A1 (Work in Progress) John Smeraglia on behalf of the HT-A1 A1: Scope and regulations Team members: Team lead Region Expertise Surendra
More informationPreface and Acknowledgments Preface and Acknowledgments to the Third Edition Preface to the Second Edition Preface to the First Edition
Preface and Acknowledgments p. xxi Preface and Acknowledgments to the Third Edition p. xxiii Preface to the Second Edition p. xxv Preface to the First Edition p. xxvii Acknowledgments to the First and
More informationAcquired Immunity 2. - Vaccines & Immunological Memory - Wataru Ise. WPI Immunology Frontier Research Center (IFReC) Osaka University.
Acquired Immunity 2 - Vaccines & Immunological Memory - Wataru Ise WPI Immunology Frontier Research Center (IFReC) Osaka University Outline 1. What is vaccine (vaccination)? 2. What is immunological memory?
More informationHumanized Mouse Models for Vaccine Development Michael A. Brehm. Why Do We Need Humanized Mouse Models?
Humanized Mouse Models for Vaccine Development Michael A. Brehm Diabetes Center of Excellence Dale Greiner Rita Bortell Philip DiIorio Nancy Phillips The Jackson Laboratory Leonard Shultz Human cells &
More informationImmunology - Lecture 2 Adaptive Immune System 1
Immunology - Lecture 2 Adaptive Immune System 1 Book chapters: Molecules of the Adaptive Immunity 6 Adaptive Cells and Organs 7 Generation of Immune Diversity Lymphocyte Antigen Receptors - 8 CD markers
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationHAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationChapter 1. Full file at
Chapter 1 1. Which is the best definition of immunity? Answer: B A. The state of having been exposed to a pathogen repeatedly B. The state of being resistant to reinfection with a pathogen C. When an individual
More informationChapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!
MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3
More informationNATURAL KILLER T CELLS EBOOK
08 April, 2018 NATURAL KILLER T CELLS EBOOK Document Filetype: PDF 90.41 KB 0 NATURAL KILLER T CELLS EBOOK Natural killer T cells (NK T cells) are a type of lymphocyte, or white blood cell. Natural killer
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationMicr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) Spring 2009 Semester
Micr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) (3 Credits) Spring 2009 Semester Course Director: (732-235-4501, ) Please note that this course is offered once every 2 years.
More informationOutline. Animals: Immunity. Defenses Against Disease. Key Concepts:
Animals: Immunity Defenses Against Disease Outline 1. Key concepts 2. Physical barriers: Skin, Mucus and HCL in stomach 3. Non-specific 4. Specific responses Immune System a. Components of Immune system
More informationUnit 5 The Human Immune Response to Infection
Unit 5 The Human Immune Response to Infection Unit 5-page 1 FOM Chapter 21 Resistance and the Immune System: Innate Immunity Preview: In Chapter 21, we will learn about the branch of the immune system
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationImmunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
More informationAutoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens
Autoimmunity Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmune disease can be caused to primary defects in B cells, T cells and possibly
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationSEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
More informationMitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective
Mitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective Mineo Matsumoto DVM, PhD, DJST Office of New Drug Ⅱ Pharmaceutical and Medical Devices Agency Disclaimers The views
More informationOverview of the Lymphoid System
Overview of the Lymphoid System The Lymphoid System Protects us against disease Lymphoid system cells respond to Environmental pathogens Toxins Abnormal body cells, such as cancers Overview of the Lymphoid
More informationONCO-HU TM MICE FOR IMMUNOTHERAPEUTIC DRUG DISCOVERY. Brian W. Soper, Ph.D. Senior Technical Information Scientist
ONCO-HU TM MICE FOR IMMUNOTHERAPEUTIC DRUG DISCOVERY Brian W. Soper, Ph.D. Senior Technical Information Scientist Presentation Outline Capabilities Humanization Hu-NSG TM versus Hu-NSG TM -SGM3 Immuno-oncology
More informationThe ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017
The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017 Jan Willem van der Laan ( EC, Europe, Regulatory Chair), Todd Bourcier (FDA, US), Tania Cavaliero (Swissmedic,
More informationChapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
More informationUnit 3 Dynamic Equilibrium Chapter Immune System
Biology 2201 Unit 3 Dynamic Equilibrium Chapter 11.4 - Immune System Compiled by S. Whalen What is Immunity? Immunity Immunity The ability of the body to fight infection and/or foreign invaders by producing
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationSelecting and interpreting markers of immunomodulation in nutrition studies. Jalil Benyacoub, PhD Nutrition & Immunity task force
Selecting and interpreting markers of immunomodulation in nutrition studies Jalil Benyacoub, PhD Nutrition & Immunity task force Outlines Overview on the immune system, immune functions and Nutrition Summary
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationCONTENTS. About the Authors, xv Contributors, xvi Preface and Acknowiedgments, xvii How to Use Your Textbook, xix About the Companion Website, xxiii
Coico, Richard Immunology 2015 About the Authors, xv Contributors, xvi Preface and Acknowiedgments, xvii How to Use Your Textbook, xix About the Companion Website, xxiii 1 OVERVIEW OF THE IMMUNE SYSTEM,
More information4) What causes lymph to move? Skeletal muscle contraction; smooth muscle contraction, breathing (like blood moves through veins)
NPHS Anatomy & Physiology UNIT 10 REVIEW GUIDE Lymphatic System 1) List the three functions of the lymphatic system. transports excess fluid to the bloodstream absorbs fats helps defend the body against
More informationBIOMARKER DRIVEN EARLY PHASE ONCOLOGY CLINICAL TRIALS; CHALLENGES IN THE REAL WORLD SID KATUGAMPOLA CENTRE FOR DRUG DEVELOPMENT CANCER RESEARCH UK
BIOMARKER DRIVEN EARLY PHASE ONCOLOGY CLINICAL TRIALS; CHALLENGES IN THE REAL WORLD SID KATUGAMPOLA CENTRE FOR DRUG DEVELOPMENT CANCER RESEARCH UK Cancer; Some Sobering Thoughts Getting cancer is one of
More informationSPECIFIC AIMS. II year (1st semester)
II year (1st semester) Scientific Field IMMUNOLOGY AND IMMUNOPATHOLOGY TUTOR ECTS MALISAN F. COORDINATOR MED/04 Immunology and Immunopathology Malisan Florence 5 MED/04 Immunology and Immunopathology Testi
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More information